What is Ionis Pharmaceuticals?
Ionis Pharmaceuticals is a rna-targeted medicines company serving providers, payers, patients, labs, hospitals, researchers, or life-sciences commercial teams.
- Category
- RNA-targeted medicines
- Headquarters
- Carlsbad, CA
- Founded
- See company profile and filings
- Employees
- Mid-market / scaled operating company
- Total funding
- Public company
- Status
- Public company; Nasdaq: IONS
What is Ionis Pharmaceuticals?
Ionis Pharmaceuticals is a rna-targeted medicines company headquartered in Carlsbad, CA.
Ionis Pharmaceuticals operates in rna-targeted medicines and has reached a scaled mid-market profile rather than an early startup footprint. Its official site and investor/company materials position the business around Antisense technology, WAINUA, Spinraza royalties, with customers using the company for repeatable operating workflows rather than one-off projects.
For sellers, Ionis Pharmaceuticals is useful to profile because the buying center is large enough to include specialized finance, IT, operations, procurement, and line-of-business owners. The company status is Public company; Nasdaq: IONS, so the best live signals are current company announcements, investor materials where available, hiring patterns, product launches, and partner ecosystem activity.
What does Ionis Pharmaceuticals offer?
Ionis Pharmaceuticals's profile centers on Antisense technology, WAINUA, Spinraza royalties, Neurology pipeline.
- Antisense technology· RNA-targeted medicines
- WAINUA· RNA-targeted medicines
- Spinraza royalties· RNA-targeted medicines
- Neurology pipeline· RNA-targeted medicines
- Cardiometabolic pipeline· RNA-targeted medicines
- Partnered medicines· RNA-targeted medicines
How does Ionis Pharmaceuticals make money?
Ionis Pharmaceuticals makes money through commercial activity tied to rna-targeted medicines.
Ionis Pharmaceuticals monetizes through the commercial model common to rna-targeted medicines: a mix of product sales, subscriptions, usage, services, channel programs, or transaction volume depending on the operating unit. Public list pricing is not always available, so enterprise buyers usually evaluate packaging, contract scope, geographic coverage, implementation services, and support commitments.
The practical growth levers are account expansion, new product attach, channel reach, retention, and operational efficiency. For outbound teams, that means relevant sales angles usually connect to productivity, integration, compliance, data quality, margin improvement, customer experience, or faster execution across distributed teams.
Who leads Ionis Pharmaceuticals?
Ionis Pharmaceuticals's named executives should be verified on the official leadership or investor-relations page before outreach.
- Ionis Pharmaceuticals executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Ionis Pharmaceuticals finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- Ionis Pharmaceuticals technology or operations leadershipTechnology, product, operations, or security leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact Ionis Pharmaceuticals's leadership?
Ionis Pharmaceuticals should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.ionis.com- Ionis Pharmaceuticals investor relationsInvestor relations / corporate contactcontact via https://www.ionis.com
- Ionis Pharmaceuticals sales or partnershipsCommercial contact routecontact via https://www.ionis.com
- Ionis Pharmaceuticals media relationsMedia or communications contact routecontact via https://www.ionis.com
How is Ionis Pharmaceuticals funded?
Ionis Pharmaceuticals's current status is Public company; Nasdaq: IONS.
Ionis Pharmaceuticals's current capital profile is best understood through its current status: Public company; Nasdaq: IONS. If the company is public, the relevant financing signals are annual reports, quarterly results, debt disclosures, buybacks, acquisitions, and capital allocation commentary rather than venture rounds.
If the company is private or recently acquired, the important seller signal is ownership context: sponsors or strategic owners often push standardization, operating metrics, procurement discipline, and integration work. In either case, budget timing should be inferred from current company announcements, earnings materials, product launches, hiring, and strategic initiatives rather than stale funding databases.
How did Ionis Pharmaceuticals get here?
Ionis Pharmaceuticals's history should be read through founding, scale-up, public/private ownership, and current product or market focus.
- FoundingIonis Pharmaceuticals is foundedThe company begins building in rna-targeted medicines.
- Scale-upCommercial footprint expandsIonis Pharmaceuticals broadens its product, customer, or geographic reach.
- Capital marketsPublic company; Nasdaq: IONSOwnership and financing context shapes procurement, reporting, and operating priorities.
- 2025Mid-market operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, current status, and public source references.
Who are Ionis Pharmaceuticals's competitors?
Ionis Pharmaceuticals competes with larger platform incumbents and focused specialists in rna-targeted medicines.
- MedtronicGlobal medical-technology incumbent with broad device and care-management scale.
- Boston ScientificLarge medical-device company competing across interventional specialties.
- AbbottHealthcare company with diagnostics, diabetes care, devices, and nutrition scale.
- Johnson & Johnson MedTechLarge medtech and pharmaceutical incumbent with global commercial reach.
- StrykerOrthopedics, neurotechnology, and surgical equipment competitor with hospital relationships.
Ionis Pharmaceuticals — frequently asked questions
